This study is testing the safety and effectiveness of the PXL-Platinum 330 system for treating corneal ectasia (a group of eye conditions where the cornea, the clear front part of your eye, thins and bulges forward). This system uses a combination of Peschke riboflavin solution and UV-A light to strengthen the cornea. You might be able to join if you are 10 years or older and have keratoconus, pellucid marginal degeneration, or post-surgical ectasia. The researchers will measure your best-corrected visual acuity (how well you can see with glasses or contacts) at 3, 6, and 12 months to see if the treatment is successful. The current status of this study is unclear, and it plans to enroll 500 participants.

Study design

This interventional study plans to enroll 500 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will undergo epithelial-on corneal crosslinking with the Peschke PXL-330 system. You will have monitoring visits for 1 year, including measurements of your corneal topography, visual acuity, eye pressure, and corneal thickness.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 1 year after treatment, with visual acuity measured at 3, 6, and 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.